Welcome to our dedicated page for ORGANON & news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on ORGANON & stock.
Organon & Co. reports developments as a global healthcare company with portfolios in Women's Health and General Medicines, including biosimilars. Company news commonly covers operating results, product and regulatory updates, and clinical data for medicines such as VTAMA cream for atopic dermatitis and plaque psoriasis, biosimilar approvals including POHERDY, and established women's health brands and devices such as Nexplanon, Follistim, and Jada.
Updates also address capital-structure disclosures, governance matters, shareholder voting topics, and material agreements, alongside the company's commercial activity across more than 140 markets.
Summary not available.
Organon (NYSE:OGN) will present eight new health economics and outcomes research abstracts at ISPOR 2026, held May 17-20, 2026 in Philadelphia.
Presentations cover contraception affordability, biosimilar adoption, VTAMA budget impact, and headache referral patterns across women’s health, dermatology, biosimilars, and neurology.
Organon (NYSE: OGN) reported Q1 2026 results: $1.460 billion revenue (down 4% as-reported; down 9% ex-FX), GAAP net income of $146 million and diluted EPS of $0.55. Adjusted EBITDA was $415 million (28.4% margin). The company announced a pending all-cash merger into Sun Pharma expected to close in early 2027, and suspended guidance and earnings calls while the transaction is pending.
Organon (NYSE: OGN) canceled its first quarter 2026 earnings conference call scheduled for May 7, 2026 after announcing on April 26, 2026 that it entered into an agreement for Sun Pharmaceutical Industries Limited to acquire Organon. Organon will release Q1 2026 results on April 30, 2026 and file a Form 10-Q with the SEC.
Organon (NYSE: OGN) and Henlius announced the European Commission approval of POHERDY® (pertuzumab) on April 29, 2026, the first approved biosimilar to PERJETA in Europe for all reference-product indications.
POHERDY is indicated in combination with trastuzumab and chemotherapy for neoadjuvant, adjuvant, and metastatic HER2‑positive breast cancer. Organon holds exclusive global commercialization rights outside China under a 2022 license agreement with Henlius.
Sun Pharma (NYSE:—) to acquire Organon (NYSE:OGN) for US$14.00 per share in an all-cash deal valuing Organon at US$11.75 billion enterprise value. Transaction expected to close in early 2027, subject to regulatory approvals and Organon stockholder vote. Combined revenue projected at US$12.4 billion.
Organon reported 2025 revenue US$6.2B, Adjusted EBITDA US$1.9B, debt US$8.6B and cash US$574M. Sun Pharma expects Net Debt/EBITDA ~2.3x post-transaction.
Organon (NYSE: OGN) will release its first quarter 2026 financial results on May 7, 2026 and will host a webcast and conference call at 8:30 a.m. ET.
The company said it does not currently expect to record any milestone expense in Q1 2026, but results are preliminary and subject to closing procedures. The live webcast and a replay (available ~two hours after the call) can be accessed on the company website; dial-in details and Conference ID are provided for analysts and investors.
Organon (NYSE: OGN) announced VTAMA® (tapinarof) cream, 1% received a strong recommendation in the American Academy of Dermatology 2026 pediatric atopic dermatitis guidelines (published April 7, 2026).
The AAD named VTAMA the only steroid-free topical supported by high certainty of evidence indicated for children aged 2 years and older across all disease severities; approvals include FDA AD indication for ages 2+ (Dec 2024).
Organon (NYSE: OGN) reported pooled Phase 3 ADORING 1 and 2 results showing VTAMA cream 1% produced early, sustained improvements in atopic dermatitis down to age 2. Significant vIGA-AD, EASI75 and PP-NRS gains appeared by week 1 and increased through week 8 versus vehicle.
The analysis (N=813) showed EASI75 57.4% vs 22.1% at week 8 and 96.9% achieved some EASI improvement by week 8. Safety events ≥3% included folliculitis, headache, upper respiratory infection, and nasopharyngitis.
Organon (NYSE: OGN) presented a pooled Phase 3 sub-analysis from ADORING 1 and 2 showing VTAMA cream, 1% produced early and sustained improvements in patient‑reported sleep subdomains for pediatric atopic dermatitis patients down to age 2 and for affected family members through Week 8.
Key results: POEM sleep scores improved versus vehicle at Week 8: -1.9 vs -0.9 (age 2–6), -1.5 vs -1.0 (7–11), -1.2 vs -0.6 (12–17). DFI sleep subdomain also improved through Week 8. Reported common treatment‑emergent AEs (≥5%) included folliculitis, headache, and nasopharyngitis.